Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

15.0%

3 terminated out of 20 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results50% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (2)
P 1 (9)
P 2 (9)

Trial Status

Recruiting8
Active Not Recruiting5
Completed3
Terminated3
Not Yet Recruiting1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05053971Phase 1Recruiting

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT04550494Phase 2Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT02595931Phase 1Active Not Recruiting

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT05642962Phase 1Active Not Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06906562Phase 2Recruiting

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

NCT04673448Phase 1Active Not Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

NCT04858009Phase 2RecruitingPrimary

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

NCT03823144Not ApplicableRecruiting

Intravital Microscopy in Human Solid Tumors

NCT06770452Phase 2RecruitingPrimary

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

NCT05038254Not ApplicableActive Not Recruiting

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

NCT03033225Phase 2Completed

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

NCT03825289Phase 1Active Not RecruitingPrimary

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

NCT05759923Phase 1Recruiting

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

NCT06759090Phase 2Not Yet RecruitingPrimary

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

NCT04390243Phase 2Terminated

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

NCT05733000Phase 2Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

NCT03818165Phase 1TerminatedPrimary

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

NCT00843830Phase 1TerminatedPrimary

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

NCT00480584Phase 1CompletedPrimary

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

NCT00137761Phase 2CompletedPrimary

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Showing all 20 trials

Research Network

Activity Timeline